vs
Side-by-side financial comparison of INSEEGO CORP. (INSG) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $48.4M, roughly 1.8× INSEEGO CORP.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 0.6%). INSEEGO CORP. produced more free cash flow last quarter ($11.6M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 13.6%).
Inseego Corp designs, manufactures and delivers advanced 5G and IoT solutions including mobile hotspots, edge computing devices, and cloud-based device management platforms. It primarily serves telecom operators, enterprise clients, and public sector customers across global markets.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
INSG vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $48.4M | $86.8M |
| Net Profit | $469.0K | — |
| Gross Margin | 42.2% | 67.4% |
| Operating Margin | 2.7% | -84.7% |
| Net Margin | 1.0% | — |
| Revenue YoY | 0.6% | 17.7% |
| Net Profit YoY | 182.9% | — |
| EPS (diluted) | $-0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $48.4M | $86.8M | ||
| Q3 25 | $45.9M | $67.5M | ||
| Q2 25 | $40.2M | $60.0M | ||
| Q1 25 | $31.7M | $49.3M | ||
| Q4 24 | $48.1M | $73.7M | ||
| Q3 24 | $54.0M | $58.6M | ||
| Q2 24 | $51.6M | $31.1M | ||
| Q1 24 | $37.5M | $715.0K |
| Q4 25 | $469.0K | — | ||
| Q3 25 | $1.4M | $-91.3M | ||
| Q2 25 | $507.0K | $-111.7M | ||
| Q1 25 | $-1.6M | $-116.2M | ||
| Q4 24 | $-566.0K | — | ||
| Q3 24 | $9.0M | $-83.5M | ||
| Q2 24 | $624.0K | $-97.1M | ||
| Q1 24 | $-4.5M | $-113.0M |
| Q4 25 | 42.2% | 67.4% | ||
| Q3 25 | 41.6% | 43.0% | ||
| Q2 25 | 41.1% | 5.5% | ||
| Q1 25 | 47.3% | -0.8% | ||
| Q4 24 | 37.3% | 68.7% | ||
| Q3 24 | 34.8% | 46.2% | ||
| Q2 24 | 36.4% | -0.8% | ||
| Q1 24 | 35.3% | — |
| Q4 25 | 2.7% | -84.7% | ||
| Q3 25 | 4.7% | -140.7% | ||
| Q2 25 | 3.2% | -189.8% | ||
| Q1 25 | -1.3% | -245.8% | ||
| Q4 24 | 3.7% | -117.5% | ||
| Q3 24 | 1.9% | -152.1% | ||
| Q2 24 | 3.6% | -327.6% | ||
| Q1 24 | -7.9% | -16464.6% |
| Q4 25 | 1.0% | — | ||
| Q3 25 | 3.1% | -135.3% | ||
| Q2 25 | 1.3% | -186.2% | ||
| Q1 25 | -5.0% | -235.5% | ||
| Q4 24 | -1.2% | — | ||
| Q3 24 | 16.6% | -142.7% | ||
| Q2 24 | 1.2% | -312.2% | ||
| Q1 24 | -11.9% | -15800.8% |
| Q4 25 | $-0.02 | — | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $-0.03 | $-0.33 | ||
| Q1 25 | $-0.16 | $-0.36 | ||
| Q4 24 | $0.62 | $-0.24 | ||
| Q3 24 | $-0.06 | $-0.28 | ||
| Q2 24 | $-0.02 | $-0.34 | ||
| Q1 24 | $-0.44 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.9M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-4.0M | $698.6M |
| Total Assets | $93.8M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.9M | $297.0M | ||
| Q3 25 | $14.6M | $300.8M | ||
| Q2 25 | $13.2M | $301.2M | ||
| Q1 25 | $35.1M | $359.7M | ||
| Q4 24 | $39.6M | $323.8M | ||
| Q3 24 | $12.0M | $397.5M | ||
| Q2 24 | $49.0M | $412.5M | ||
| Q1 24 | $12.3M | $356.2M |
| Q4 25 | $-4.0M | $698.6M | ||
| Q3 25 | $-7.7M | $702.3M | ||
| Q2 25 | $-10.5M | $698.5M | ||
| Q1 25 | $-13.0M | $767.9M | ||
| Q4 24 | $-12.9M | $710.4M | ||
| Q3 24 | $-85.1M | $773.5M | ||
| Q2 24 | $-101.8M | $768.5M | ||
| Q1 24 | $-105.6M | $680.0M |
| Q4 25 | $93.8M | $913.2M | ||
| Q3 25 | $85.8M | $904.9M | ||
| Q2 25 | $83.1M | $907.4M | ||
| Q1 25 | $93.0M | $966.7M | ||
| Q4 24 | $100.0M | $910.4M | ||
| Q3 24 | $113.4M | $991.1M | ||
| Q2 24 | $149.6M | $964.3M | ||
| Q1 24 | $122.1M | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $12.0M | $-52.6M |
| Free Cash FlowOCF − Capex | $11.6M | $-61.9M |
| FCF MarginFCF / Revenue | 24.0% | -71.3% |
| Capex IntensityCapex / Revenue | 0.7% | 10.7% |
| Cash ConversionOCF / Net Profit | 25.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | $6.5M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $12.0M | $-52.6M | ||
| Q3 25 | $3.2M | $-78.7M | ||
| Q2 25 | $-4.5M | $-67.4M | ||
| Q1 25 | $-3.5M | $-103.7M | ||
| Q4 24 | $-14.2M | $-73.3M | ||
| Q3 24 | $14.8M | $-59.0M | ||
| Q2 24 | $27.6M | $-98.4M | ||
| Q1 24 | $5.2M | $-122.3M |
| Q4 25 | $11.6M | $-61.9M | ||
| Q3 25 | $3.1M | $-89.5M | ||
| Q2 25 | $-4.7M | $-74.9M | ||
| Q1 25 | $-3.5M | $-109.9M | ||
| Q4 24 | $-14.3M | $-77.5M | ||
| Q3 24 | $14.8M | $-61.3M | ||
| Q2 24 | $27.6M | $-98.9M | ||
| Q1 24 | — | $-126.5M |
| Q4 25 | 24.0% | -71.3% | ||
| Q3 25 | 6.7% | -132.7% | ||
| Q2 25 | -11.6% | -124.9% | ||
| Q1 25 | -11.0% | -222.8% | ||
| Q4 24 | -29.7% | -105.1% | ||
| Q3 24 | 27.4% | -104.6% | ||
| Q2 24 | 53.5% | -317.9% | ||
| Q1 24 | — | -17685.3% |
| Q4 25 | 0.7% | 10.7% | ||
| Q3 25 | 0.2% | 16.1% | ||
| Q2 25 | 0.5% | 12.4% | ||
| Q1 25 | 0.1% | 12.6% | ||
| Q4 24 | 0.1% | 5.7% | ||
| Q3 24 | 0.0% | 3.9% | ||
| Q2 24 | 0.0% | 1.4% | ||
| Q1 24 | 0.0% | 583.4% |
| Q4 25 | 25.50× | — | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | -8.81× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.65× | — | ||
| Q2 24 | 44.31× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INSG
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
